Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2).
BACKGROUND
The aim of this study was to investigate the safety of neoadjuvant chemoradiation using radiotherapy (RT) combined with concurrent capecitabine and irinotecan for locally advanced rectal cancer before surgery.


METHODS
Forty-six patients were recruited and treated on the basis that MRI scanning had shown poor-risk tumours with threatening (< or =1 mm) or involvement of the mesorectal fascia. Conformal RT was given using 3 or 4 fields at daily fractions of 1.8 Gy on 5 days per week to a total dose of 45 Gy. Concurrently oral capecitabine was given twice daily throughout radiotherapy continuously from days 1 to 35 and intravenous irinotecan was given once per week during weeks 1 to 4 of RT. Dose levels were gradually escalated as follows. Dose level 1: capecitabine 650 mg m(-2) b.i.d. and irinotecan 50 mg m(-2); Dose level 2: capecitabine 650 mg m(-2) b.i.d. and irinotecan 60 mg m(-2); Dose level 3: capecitabine 825 mg m(-2) b.i.d. and irinotecan 60 mg m(2); Dose level 4: capecitabine 825 mg m(-2) b.i.d. and irinotecan 70 mg m(-2).


RESULTS
Diarrhoea (grade 3, no grade 4) was the main serious acute toxicity with lesser degrees of fatigue, neutropenia, anorexia and palmar-plantar erythrodysesthesia. The recommended dose for future study was dose level 2 at which 3 of 14 patients (21%) developed grade 3 diarrhoea. Postoperative complications included seven pelvic or wound infections and two anastomotic and two perineal wound dehiscences. There were no deaths in the first 30 days postoperatively. Of 41 resected specimens, 11 (27%) showed a pathological complete response (pCR) and five (12%) showed an involved circumferential resection margin (defined as < or =1 mm). The 3-year disease-free survival (intent-to-treat) was 53.2%.


CONCLUSIONS
In patients with poor-risk MRI-defined locally advanced rectal cancer threatening or involving the mesorectal fascia, preoperative chemoradiation based on RT at 45 Gy in 25 daily fractions over 5 weeks with continuous daily oral capecitabine at 650 mg m(-2) b.i.d. days 1-35 and weekly IV irinotecan at 60 mg m(-2) weeks 1-4, provides acceptable acute toxicity and postoperative morbidity with encouraging response and curative resection rates.
Gollins
S W
SW
Department of Clinical Oncology, North Wales Cancer Treatment Centre, Rhyl LL18 5UJ, UK. simon.gollins@cd-tr.wales.nhs.uk
Myint
S
S
Susnerwala
S
S
Haylock
B
B
Wise
M
M
Topham
C
C
Samuel
L
L
Swindell
R
R
Morris
J
J
Mason
L
L
Levine
E
E
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000069287:Capecitabine; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D000077146:Irinotecan; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000473:pathology / Q000628:therapy*
D003841:Deoxycytidine; D000069287:Capecitabine; D000077146:Irinotecan; D005472:Fluorouracil; D002166:Camptothecin
N Engl J Med. 2004 Oct 21;351(17):1731-40
15496622
J Clin Oncol. 2006 Feb 1;24(4):650-5
16446336
J Clin Oncol. 2005 Mar 1;23(7):1350-7
15684318
Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1311-20
12654443
Br J Cancer. 2008 Apr 8;98(7):1210-6
18349840
Dis Colon Rectum. 2002 Jul;45(7):857-66
12130870
Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):745-52
16199310
N Engl J Med. 2006 Sep 14;355(11):1114-23
16971718
Dis Colon Rectum. 1998 Aug;41(8):979-83
9715152
Br J Cancer. 2005 Apr 11;92(7):1215-20
15785742
Lancet. 1986 Nov 1;2(8514):996-9
2430152
Radiother Oncol. 2007 Dec;85(3):379-84
18036687
Clin Cancer Res. 1999 Oct;5(10):2948-53
10537364
Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):132-7
12504045
Cancer Res. 1997 Apr 15;57(8):1529-36
9108456
BMJ. 2006 Oct 14;333(7572):779
16984925
Lancet. 2001 Oct 20;358(9290):1291-304
11684209
Br J Cancer. 2006 Apr 10;94(7):976-81
16552435
J Clin Oncol. 2008 Jan 10;26(2):303-12
18182672
Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):201-5
16814947
Lancet. 2009 Mar 7;373(9666):821-8
19269520
Ann Oncol. 2006 Mar;17(3):361-71
16500912
Br J Cancer. 2007 Feb 26;96(4):551-8
17262086
Br J Cancer. 2007 Mar 26;96(6):912-7
17325705
Lancet. 1993 Feb 20;341(8843):457-60
8094488
J Clin Oncol. 2006 Oct 1;24(28):4620-5
17008704
N Engl J Med. 2001 Aug 30;345(9):638-46
11547717
Ann Surg. 2002 Apr;235(4):449-57
11923599
Am J Surg Pathol. 2002 Mar;26(3):350-7
11859207